It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.<\/p>
<\/p>
NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England\u2019s offer, we are pleased to hear that it has responded positively to NHS England\u2019s and NICE\u2019s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O\u2019Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-09-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "171384"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-09-14T13:32:27.67Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-09-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4450", "label" : {"_value" : "Biography information for Luke Hall"} } , "tablingMemberConstituency" : {"_value" : "Thornbury and Yate"} , "tablingMemberPrinted" : [{"_value" : "Luke Hall"} ], "uin" : "171383"} , {"_about" : "http://data.parliament.uk/resources/969031", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/969031/answer", "answerText" : {"_value" : "
It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.<\/p>
<\/p>
NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England\u2019s offer, we are pleased to hear that it has responded positively to NHS England\u2019s and NICE\u2019s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O\u2019Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-09-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "171383"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-09-14T13:32:27.717Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-09-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care of 17 July 2018, Official Report, column 384, what progress the Government has made on access to Orkambi in England since Vertex Pharmaceuticals was called on to accept NHS England\u2019s proposal to make that drug available to people with cystic fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4450", "label" : {"_value" : "Biography information for Luke Hall"} } , "tablingMemberConstituency" : {"_value" : "Thornbury and Yate"} , "tablingMemberPrinted" : [{"_value" : "Luke Hall"} ], "uin" : "171384"} , {"_about" : "http://data.parliament.uk/resources/969040", "AnsweringBody" : [{"_value" : "Women and Equalities"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/969040/answer", "answerText" : {"_value" : "In March this year, the Government announced its intention to commence Section 36 of the Equality Act 2010 in its response to the Women and Equalities Select Committee report on disability and the built environment. The announcement made clear that further work on identifying and assessing any additional burdens on local authorities is first required before a commencement date can be given. We hope to make an announcement on timing of commencement of Section 36 of the Equality Act 2010 as soon as possible. "} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4399", "label" : {"_value" : "Biography information for Victoria Atkins"} } , "answeringMemberConstituency" : {"_value" : "Louth and Horncastle"} , "answeringMemberPrinted" : {"_value" : "Victoria Atkins"} , "dateOfAnswer" : {"_value" : "2018-09-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-09-19T08:43:54.297Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "31"} , "answeringDeptShortName" : {"_value" : "Women and Equalities"} , "answeringDeptSortName" : {"_value" : "Women and Equalities"} , "date" : {"_value" : "2018-09-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Equality Act 2010"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Minister for Women and Equalities, what progress the Government has made on the implementation of section 36 of the Equality Act 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4006", "label" : {"_value" : "Biography information for Dr Matthew Offord"} } , "tablingMemberConstituency" : {"_value" : "Hendon"} , "tablingMemberPrinted" : [{"_value" : "Dr Matthew Offord"} ], "uin" : "171364"} , {"_about" : "http://data.parliament.uk/resources/969045", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/969045/answer", "answerText" : {"_value" : "
Crime figures for England and Wales are published quarterly by the Office for National Statistics (ONS) and incorporate police recorded crime (PRC) and the independent Crime Survey for England and Wales (CSEW). The table below shows the latest changes in PRC for London for the year ending March 2018 compared to the previous year.<\/p>
<\/p><\/td> | <\/p><\/td> | <\/p><\/td> | Year ending <\/strong><\/p><\/td> % change <\/strong><\/p><\/td><\/tr> <\/p><\/td> Mar-17<\/strong><\/p><\/td> Mar-18<\/strong><\/p><\/td><\/tr> Total recorded crime <\/strong><\/p><\/td> 774,734<\/strong><\/p><\/td> <\/p><\/td> 820,920<\/strong><\/p><\/td> 6%<\/strong><\/p><\/td><\/tr> Violence against the person<\/p><\/td> 192,979<\/p><\/td> <\/p><\/td> 201,125<\/p><\/td> 4%<\/p><\/td><\/tr> Sexual offences<\/p><\/td> 17,668<\/p><\/td> <\/p><\/td> 19,804<\/p><\/td> 12%<\/p><\/td><\/tr> Robbery<\/p><\/td> 24,174<\/p><\/td> <\/p><\/td> 32,751<\/p><\/td> 35%<\/p><\/td><\/tr> Burglary<\/p><\/td> 69,493<\/p><\/td> <\/p><\/td> 76,727<\/p><\/td> 10%<\/p><\/td><\/tr> Shoplifting<\/p><\/td> 48,102<\/p><\/td> <\/p><\/td> 47,014<\/p><\/td> -2%<\/p><\/td><\/tr> Theft offences<\/p><\/td> 376,567<\/p><\/td> <\/p><\/td> 405,122<\/p><\/td> 8%<\/p><\/td><\/tr> Criminal damage and arson<\/p><\/td> 62,652<\/p><\/td> <\/p><\/td> 60,054<\/p><\/td> -4%<\/p><\/td><\/tr> Drug offences<\/p><\/td> 37,520<\/p><\/td> <\/p><\/td> 35,696<\/p><\/td> -5%<\/p><\/td><\/tr><\/tbody><\/table> |